SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

C42 - Cerebrovascular Disease II: Hemorrhagic Stroke

Event Time: Sunday April 23, 2017 1:00 pm to 3:00 pm
Topic(s): Cerebrovascular Disease and Interventional Neurology
Director(s): Philip Gorelick MD, MPH, FAAN
Description: Hemorrhagic stroke is an important cause of morbidity and mortality. This course will focus on intraparenchymal hemorrhage (IPH) and aneurysmal subarachnoid hemorrhage (SAH). Course participants will become familiar with basic diagnostic and management recommendations for IPH and SAH, up-to-date guidance statements, and the role of endovascular therapies and new clinical trial data for the diagnosis and management of IPH and SAH. This program complements C30: Cerebrovascular Disease I: Prevention and C59: Cerebrovascular Disease III: Acute Ischemic Stroke, but covers independent topics.
Completion Message: Participants should be able to discuss key diagnostic and management recommendations for IPH and SAH, discuss key scientific guidance recommendations for diagnosis and management of IPH and SAH, and discuss the role of endovascular therapies and recent clinical trial data in diagnosis and management of IPH and SAH.
CME Credits: 2
Core Competencies: Medical Knowledge, Patient Care

Program Speakers - Tentative

Start/End Time Title Faculty
1:00 PM - 1:35 PM Evidence-based Diagnosis and Management of Intraparenchymal Hemorrhage Venkatesh Aiyagari MD 
1:35 PM - 1:45 PM Questions and Answers Venkatesh Aiyagari MD 
1:45 PM - 2:20 PM Evidence-based Diagnosis and Management of Aneurysmal Subarachnoid Hemorrhage Sean Ruland MD 
2:20 PM - 2:30 PM Questions and Answers Sean Ruland MD 
2:30 PM - 2:55 PM Aspirin: Benefits and Bleeding Risks Philip Gorelick MD, MPH, FAAN 
2:55 PM - 3:00 PM Questions and Answers Philip Gorelick MD, MPH, FAAN 

Disclosures

Speaker Disclosure
Venkatesh Aiyagari, MD Dr. Aiyagari has nothing to disclose.

Philip B. Gorelick, MD, MPH, FAAN Dr. Gorelick has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cardiometabolic Health Congress for lectures on atrial fibrillation, Amgen for serving on a data safety and monitoring board for a CGRP inhibitor, and Novartis for serving on a data safety and monitoring board for LCZ 696 in heart failure. .

Sean D. Ruland, MD Dr. Ruland has nothing to disclose.

Register Now

Related Courses

Saturday April 21, 2018

1:30 PM-3:30 PM
C21 Stroke in Young Adults and Women Aneesh Singhal MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C29 Controversies in Stroke Treatment and Prevention Steven Messe MD, FAAN, FAHA

Monday April 23, 2018

7:00 AM-9:00 AM
C64 Update on Medical Management of Stroke Natalia Rost MD, MPH, FAAN
1:00 PM-3:00 PM
C75 Therapeutic Temperature Modulation in the ICU Stephan Mayer MD

Tuesday April 24, 2018

1:00 PM-3:00 PM
C115 Cerebrovascular Disease I: Prevention Larry Goldstein MD, FAAN, FAHA
3:30 PM-5:30 PM
C129 Cerebrovascular Disease II: Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke Philip Gorelick MD, MPH, FAAN

Wednesday April 25, 2018

1:00 PM-3:00 PM
C151 Cerebrovascular Disease III: Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke Philip Gorelick MD, MPH, FAAN
3:30 PM-5:30 PM
C166 Cerebrovascular Disease IV: Telestroke Eric Anderson MD, PhD

Thursday April 26, 2018

1:00 PM-3:00 PM
C195 Spanish: Update on Stroke Therapy Carlos Kase MD, FAAN, FAHA
3:30 PM-5:30 PM
C203 Endovascular Treatment of Acute Stroke and Cerebrovascular Disease Dileep Yavagal MD, FAAN

Friday April 27, 2018

7:00 AM-9:00 AM
C217 Current Management of Incidental and Asymptomatic Cerebrovascular Lesions Seemant Chaturvedi MD, FAAN, FAHA

MEMBER LOG IN

Forgot Password?